Clinical Trial Update: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating camrelizumab plus neoadjuvant chemotherapy or chemoradiotherapy against chemoradiotherapy alone in resectable esophageal squamous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Zhigang Li | Conditions: Resectable Esophageal Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING